Tocris/Anandamide (in Tocrisolve™ 100)/1017/10/10 mg

Biological Activity

Endogenous cannabinoid and vanilloid receptor agonist, in water-soluble emulsion (for details see Tocrisolve^TM 100, Cat. No. 1684). K_i values are 89 and 371 nM for CB₁ and CB₂ receptors respectively; EC₅₀ values are 18, 31 and 27 nM at GPR55, CB₁ and CB₂ respectively; pK_i = 5.68 for rVR1. Also blocks TNF-α-induced NF-kB activation via direct inhibition of IKK. Also available as the pure oil dissolved in ethanol (Anandamine, Cat. No. 1339). Tocrisolve Control (Cat. No. 1684) also available.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Preparing Stock Solutions

The following data is based on the product molecular weight 347.54. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Product Datasheets

References

References are publications that support the products' biological activity.

Gardiner et al (2002) Complex regional haemodynamic effects of anandamide in conscious rats. Br.J.Pharmacol. 135 1889 PMID: 11959791

Kagaya et al (2002) Characterization of the anandamide-induced depolarization of guinea-pig isolated vagus nerve. Br.J.Pharmacol. 137 39 PMID: 12183329

Pertwee (1999) Pharmacology of cannabinoid receptor ligands. Curr.Med.Chem. 6 635 PMID: 10469884

Ross et al (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br.J.Pharmacol. 132 631 PMID: 11159715

Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092 PMID: 17876302

Sancho et al (2003) Anandamide inhibits nuclear factor-κB activation through a cannabinoid receptor-independent pathway. Mol.Pharmacol. 63 429 PMID: 12527815